HSR22-128: Patient-Level Barriers to Surveillance for Hepatocellular Carcinoma Among Patients With Chronic Liver Disease From the Provider Perspective

Authors:
Eliza Wright Beal The Center for Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH
College of Medicine, The Ohio State University, Columbus, OH
Ohio State University Comprehensive Cancer Center, Columbus, OH

Search for other papers by Eliza Wright Beal in
Current site
Google Scholar
PubMed
Close
 MD
,
Leva Gorji College of Medicine, The Ohio State University, Columbus, OH

Search for other papers by Leva Gorji in
Current site
Google Scholar
PubMed
Close
 DO
,
Jaclyn Volney The Center for Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH

Search for other papers by Jaclyn Volney in
Current site
Google Scholar
PubMed
Close
 MPH
,
Lindsey Sova The Center for Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH

Search for other papers by Lindsey Sova in
Current site
Google Scholar
PubMed
Close
 MPH
,
Ann McAlearney The Center for Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH
College of Medicine, The Ohio State University, Columbus, OH

Search for other papers by Ann McAlearney in
Current site
Google Scholar
PubMed
Close
 ScD
, and
Allan Tsung The Center for Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH
College of Medicine, The Ohio State University, Columbus, OH
Ohio State University Comprehensive Cancer Center, Columbus, OH

Search for other papers by Allan Tsung in
Current site
Google Scholar
PubMed
Close
 MD
View More View Less
Full access

Background: Most cases of hepatocellular carcinoma (HCC) occur in high-risk patients. Guidelines from expert societies recommend HCC surveillance with ultrasound with or without serum alpha fetoprotein every 6 months for these patients, but fewer than 20% undergo recommended surveillance. The objective of this study was to identify patient-level barriers to surveillance from the provider perspective. Methods: Qualitative research methods were employed. Purposive sampling was used to invite primary care providers from the Departments of Internal Medicine and Family and Community Medicine and specialty providers from the Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, to participate. A semi-structured guide was used to conduct one-on-one interviews. Transcribed interviews were analyzed to reveal emergent themes. Results: 22 providers were interviewed including physicians and nurse practitioners in primary care, gastroenterology and hepatology. Providers reported various patient-level barriers to HCC surveillance including transportation, travel distance, insurance issues, scheduling difficulties, distrust of the medical community, language barriers, busy life obligations, difficulty obtaining time off work, inadequate support systems, difficulty coordinating with local centers, religious fatalism, continued substance abuse, and poor health literacy (Table). Conclusions: Providers identified many important patient-level barriers to HCC surveillance in high-risk patients. Future research should focus on the design, testing and implementation of interventions to target and address these patient-level barriers and improve HCC surveillance in this population.

HSR22-128 Table

T1

Corresponding Author: Eliza Wright Beal, MD
  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 156 75 1
PDF Downloads 0 0 0
EPUB Downloads 0 0 0